Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine

Vaccine

Volumn 29, Issue 40, 2011, Pages 7020-7026

  Jones, Frank R ^a   Gabitzsch, Elizabeth S ^a   Xu, Younong ^a   Balint, Joseph P ^a   Borisevich, Viktoriya ^b   Smith, Jennifer ^b   Smith, Jeanon ^b   Peng, Bi Hung ^b   Walker, Aida ^b   Salazar, Magda ^b   Paessler, Slobodan ^b  

^a Etubics Corporation   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Ad5 E1 , E2b ; Adenovirus vector; Cell mediated immunity; H1N1 vaccine; Hemagglutinin; Horizontal transmission; Influenza; Neuraminidase; Pandemic; Viral shedding

Indexed keywords

ADENOVIRUS VECTOR; HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENE SEQUENCE; GENE SYNTHESIS; GENE THERAPY; IMMUNE RESPONSE; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS SHEDDING; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CONSENSUS; FERRETS; GENETIC VECTORS; HEMAGGLUTININS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; NASAL LAVAGE FLUID; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 80052327605     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.073     Document Type: Article

References (38)

1. Taubenberger J.K., Morens D.M. Influenza: the once and future pandemic. Public Health Rep 2010, 3:16-26.
2. Lu J., Liu D., Lui W., Shi T., Tong Y., Cao W. Genetic stability and linkage analysis of the 2009 influenza A(H1N1) virus based on sequence homology. Arch Virol 2009, 154:1883-1890.
3. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) viruses circulating in humans. Science 2009, 325:197-201.
4. Uyeki T.M. 2009 H1N1 virus transmission and outbreaks. N Engl J Med 2010, 362:2221-2223.
5. Janies D.A., Voronkin I.O., Studer J., Hardman J., Alexandrov B.B., Treseder T.W., et al. Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages. Int J Health Geogr 2010, 9:13.
6. http://www.cdc.gov/flu/weekly/fluactivity.htm.
7. http://www.npr.org/blogs/health/2009/07/manufacturing_problems_with_sw.html.
8. Fitzpatrick M. Excess H1N1 vaccine could be sold, kept in reserve. The Vancouver Sun 2010, 10(January).
9. http://www.medscape.com/viewarticle/702229.
10. Amalfitano A., Begy C.R., Chamberlain J.S. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc Natl Acad Sci USA 1996, 93:3352-3356.
11. Hodges B.L., Serra D., Hu H., Begy C.A., Chamberlain J.S., Amalfitano A. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J Gene Med 2000, 2:250-259.
12. Amalfitano A., Hauser M.A., Hu H., Serra D., Begy C.R., Chamberlain J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998, 72:926-933.
13. Gabitzsch E.S., Xu Y., Yoshida L.H., Balint J., Gayle R.B., Amalfitano A., et al. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant based vaccine used to induce cell mediated immune responses. Immunol Lett 2009, 122:44-51.
14. Gabitzsch E.S., Xu Y., Balint J.P., Hartman Z.C., Lyerly H.K., Jones F.R. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunol Immunother 2010, 59:1131-1135.
15. Gabitzsch E.S., Xu Y., Yoshida L.H., Balint J., Amalfitano A., Jones F.R. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 2009, 27:6394-6398.
16. Gabitzsch E.S., Xu Y., Balcaitis S., Balint J.P., Jones F.J. An Ad5 [E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Ther 2011, (January (14)). [Epub ahead of print].
17. Osada T., Yang X.Y., Hartman Z.C., Glass O., Hodges B.L., Niedzwiecki D., et al. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 2009, 16:673-682.
18. Yun N.E., Linde N.S., Zacks M.A., Barr I.G., Hurt A.C., Smith J.N., et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008, 374:198-209.
19. van der Laan J.W., Herberts C., Lambkin-Williams R., Boyers A., Mann A.J., Oxford J. Animal models in influenza vaccine testing. Expert Rev Vaccines 2008, 7:783-793.
20. Yap K.L., Ada G.L., McKenzie I.F. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978, 273:238-239.
21. Bender B.S., Rowe C.A., Taylor S.F., Wyatt L.S., Moss B., Small P.A. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 1996, 70:6418-6424.
22. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
23. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189:991-998.
24. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23:5404-5410.
25. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V., McMichael A.J. Rapid effector function in CD8+ memory T cells. J Exp Med 1997, 186:859-865.
26. Sambhara S., Woods S., Arpino R., Kurichh A., Tamane A., Underdown B., et al. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J Infect Dis 1998, 177:1266-1274.
27. Sambhara S., Kurichh A., Miranda R., Tumpey T., Rowe T., Renshaw M., et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 2001, 211:143-153.
28. Epstein S.L., Lo C.Y., Misplon J.A., Lawson C.M., Hendrickson B.A., Max E.E., et al. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-defiecnt, and J chain deficient-mice. J Immunol 1997, 158:1222-1230.
29. Fiers W., Neirynck S., Deroo T., Saelens X., Jou W.M. Soluble recombinant influenza vaccines. Philos Trans R Soc Lond B Biol Sci 2001, 356:1961-1963.
30. Wang F., Yang W., Fang F., Chang H., Yu P., Chen Z. Essential sequence of influenza B virus hemagglutinin DNA to provide protection against lethal homologous viral infection. DNA Cell Bio 2008, 27:377-385.
31. Ledgerwood J.E., Costner P., Desai N., Holman L., Enama M.E., Yamshchikov G., et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010, 29:304-313.
32. Geisbert T.W., Baily M., Geisbert J.B., Asiedu C., Roederer M., Grazia-Pau M. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol 2010, 84:10386-10394.
33. Branco L.M., Grove J.N., Geske F.J., Boisen M.L., Muncy I.J., Magliato S.A., et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J 2010, 7:279.
34. McKibbin W., Sidorenko D. Global macroeconmic consequences of pandemic influenza. Presentations at ACHERH Forum 2006 2006.
35. http://www.clinicaltrials.gov/ct2/results%3Fterm=Etubics.
36. WHO. WHO Manual on Animal Influenza Diagnosis and Surveillance 2002.
37. Hobeika A.C., Clay T.M., Mosca P.J., Lyerly H.K., Morse M.A. Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit Rev Immunol 2001, 21:287-297.
38. Hobeika A.C., Morse M.A., Osada T., Ghanayem M., Niedzwiecki D., Barrier R., et al. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 2005, 28:63-72.